INTRODUCTION

Every year, seasonal influenza viruses are estimated to cause globally >100 million episodes of illness and 870,000 hospitalizations for acute lower respiratory infection among children under 5 years of age. Children under 1 year of age are at the highest risk for influenza-attributable hospitalizations, and the youngest infants are frequently admitted due to sepsis-like symptoms.2-7
Influenza-associated childhood mortality rates are also highest among the youngest children. Furthermore, children have a central role in the transmission of influenza in the community. Prediction of influenza in young infants is difficult. Influenza vaccines are licensed for use only in children older than 6 months of age, and the response to influenza vaccination in young infants is generally weaker than in older children. Maternal influenza vaccination during pregnancy reduces the risk of influenza in infants, but the duration of protection afforded by maternal antibodies is limited. Because most infants probably contract influenza from their family members, influenza vaccination of the other family members might provide some protection for infants too young to be vaccinated themselves. In many cases, however, the only way of reducing the burden of influenza in infants is by ameliorating the illness by the use of oseltamivir treatment.

Although the high rates of influenza-associated hospitalization among young infants have been described in several studies, most young infants are seen and treated as outpatients. Only limited data exist on the clinical features and overall burden of influenza among outpatient children during their first year of life. The aim of this study was to assess the incidence, clinical presentation, and complications of influenza virus infections in a prospectively followed cohort of newborn infants during their first influenza season.

### 2 METHODS

#### 2.1 Study design

This prospective cohort study was performed at a primary care study clinic in Turku, Finland, from September 1, 2017, to June 30, 2018. Before the study period, 431 children born in June-August 2017 at Turku University Hospital were enrolled in a follow-up cohort. The parents of newborn children received written information about the study at the maternal ward of the hospital soon after the child was born, and those who wanted their child to participate signed an informed consent form. Of all children born during the enrollment period, approximately half were enrolled in this study. The study protocol was approved by the Ethics Committee of the Hospital District of Southwest Finland (approval number 47/1801/2017).

#### 2.2 Study conduct

The study clinic was open every day during the 10-month study period, including weekends and holidays. The parents were instructed to bring their child for clinical examination at the study clinic as soon as possible after the onset of fever or any signs of respiratory infection. During each visit, a study physician examined the child, filled out a structured medical record, and obtained nasopharyngeal swab specimens for determination of the viral etiology of the illness. The structured medical record contained detailed questions about the presence and duration of the child’s preceding signs and symptoms and detailed findings at the clinical examination. Oseltamivir treatment was given to all children who were diagnosed with a laboratory-confirmed influenza within 48 hours of illness onset. The dosage of oseltamivir was 3 mg/kg twice daily for 5 days.

The children were routinely re-examined on days 5-7 after the onset of illness and additionally whenever the parents deemed it necessary, especially if they suspected the worsening of the disease or the development of a complication such as acute otitis media (AOM). All visits were free of charge to the families, and there was no limit for the number of visits during the study.

Background information regarding the family, pregnancy, and delivery was obtained from the parents of all children. The parents were provided with symptom diaries (one for September-January and another for February-June) that they were asked to complete daily throughout the 10-month follow-up period. Children were considered active participants if they visited the study clinic at least once or if the parents returned at least one of the two symptom diaries, and if the parents did not inform the study personnel that their child had been treated for a respiratory illness somewhere else than at the study clinic. The baseline characteristics of the 408 active participants are shown in Table 1.

| Characteristic                  | No. of children | %  |
|---------------------------------|-----------------|----|
| Sex                             |                 |    |
| Male                            | 208             | 51.0|
| Female                          | 200             | 49.0|
| Age at start of follow-up (mo)  |                 |    |
| <1                              | 133             | 32.6|
| 1-<2                            | 163             | 40.0|
| 2-<3                            | 112             | 27.5|
| Birth weight (g)                |                 |    |
| <2500                           | 23              | 5.6 |
| 2500-3999                       | 313             | 76.7|
| ≥4000                           | 72              | 17.6|
| Method of delivery              |                 |    |
| Vaginal                         | 349             | 85.5|
| Cesarean section                | 59              | 14.5|
| Gestational age (wk)            |                 |    |
| <37                             | 27              | 6.6 |
| 37-41                           | 367             | 90.0|
| ≥42                             | 14              | 3.4 |
| No. of siblings                 |                 |    |
| 0                               | 178             | 43.6|
| 1                               | 142             | 34.8|
| ≥2                              | 88              | 21.6|
| Parental smoking                | 77              | 18.9|
| Influenza vaccination           | 54              | 14.2 |

*Data on vaccination were available for 379 children.*
3.2 Clinical presentation at the initial visit

Five episodes of influenza were excluded from all analyses of clinical findings because of confirmed double viral infections in which influenza A or B virus was not the predominant virus (rhinovirus, 3 cases; respiratory syncytial virus, 2 cases). Among the remaining 50 influenza episodes, influenza A virus was detected in 26 (52.0%) and influenza B virus in 24 (48.0%) cases.

The signs and symptoms and clinical findings at the initial visit in children with influenza are presented in Table 2. Overall, 48 (96.0%) of 50 children had some fever, and 23 (46.0%) had fever ≥39.0°C; the mean maximum fever at or before the initial visit for influenza was 38.8°C. No child had a sepsis-like clinical presentation. Rhinitis was present in 41 (82.0%) children, and 37 (74.0%) children had cough. Gastrointestinal symptoms were present in 11 (22.0%) children. None of the differences between influenza A and B infections were statistically significant.

3.3 Duration of symptoms

The median duration of preceding symptoms before the initial visit was 17.6 hours (interquartile range [IQR], 9.5-43.0). The duration of preceding symptoms was 13.5 hours (IQR, 7.5-23.8) in children with influenza A and 26.8 hours (IQR, 11.3-76.4) in children with influenza B (P = .035). The overall median duration of illness in children with influenza was 8.0 days (IQR, 6.0-11.3), and the median duration of fever was 3.0 days (IQR, 1.8-4.0); no differences were observed between influenza A and B illnesses.
Complications and management

The most frequent complication of influenza was AOM which was diagnosed in 23 (46.0%) of 50 children; 11 (47.8%) of all 23 cases of AOM were diagnosed during the follow-up visits after the initial clinical examination. None of the children had pneumonia. A total of 21 (42.0%) children were treated with antibiotics; all treatments were for AOM. One (2.0%) child was hospitalized because of febrile convulsion.

Overall, 40 (80.0%) of 50 children with influenza came to the initial visit within 48 hours of the onset of symptoms, and influenza was virologically confirmed during the first 48 hours of symptoms in 37 (74.0%) children; all these children received oseltamivir treatment for 5 days. One child with influenza was cared for outside home and was absent from day care because of influenza.

Effectiveness of influenza vaccination

Data on seasonal influenza vaccination in the family were available for 379 children. Of the 54 children who had been vaccinated against influenza, 4 (7.4%) were diagnosed with influenza. Among the 325 unvaccinated children, influenza was diagnosed in 46 (14.2%) cases, corresponding to a vaccine effectiveness of 48% (95% CI, −29%–80%; P = .17). The type-specific effectiveness of vaccination was 52% (95% CI, −72%–87%; P = .29) against influenza A and 45% (95% CI, −97%–86%; P = .39) against influenza B. Of the 325 unvaccinated children, 123 (37.8%) lived in households in which all other family members had received influenza vaccination for the season. Seventeen (13.8%) of these 123 children were diagnosed with influenza, compared with 29 of 202 (14.4%) children living in households in which at least one of the other family members had not been vaccinated (vaccine effectiveness 4%; 95% CI, −66%–45%; P = .89). The effectiveness of vaccination against influenza-associated AOM was 5% (95% CI, −182%–70%; P = .93).

DISCUSSION

This prospective cohort study provides detailed data about the clinical features and overall burden of influenza in a large and
representative group of young infants followed carefully throughout their first influenza season. Although virtually all infants in the cohort were taken care of at home, 13% of them contracted a laboratory-confirmed influenza. In almost half of children with influenza, the course of illness was complicated by the development of AOM that was mostly treated with antibiotics. Our study also confirms that the greatest part of the total burden of influenza even among the youngest children occurs in the outpatient setting. Although none of the infants had had prior exposure to influenza viruses and only a minor proportion of them were vaccinated, only one child was hospitalized with influenza.

Our observed incidence rate of influenza during the first year of life is comparable with previous results among older children that have demonstrated annual influenza attack rates of 10%-20% in children. In one recent follow-up study, the incidence of laboratory-confirmed influenza among young children during their first influenza season was only 5%. One potential explanation for the difference is in the study design; in that previous study, substantial numbers of nasal swab samples were obtained at home by the parents who mailed the specimens to the laboratory, and eventually, a specimen for viral diagnosis was available for approximately half of all respiratory infections in the cohort. However, it is also well-known that influenza epidemics vary in intensity and severity, and the attack rates could be lower than average during any milder influenza seasons.

In this study, AOM was diagnosed as a complication of influenza in 46% of young children, which is in agreement with previous studies and demonstrates that influenza viruses belong to the most important viruses predisposing children to AOM. It is worth noticing that about half of all cases of AOM developed after the first visit to the study clinic. This is in line with studies showing that the incidence of AOM peaks on days 3-4 after the onset of symptoms of a viral respiratory infection, and it emphasizes the importance of clinical re-examinations to capture all cases of AOM.

In previous studies, fever has been the strongest sign associated with influenza and that applied also to the infants in our study. However, as observed also previously, rhinitis and cough were frequently present already in the early phase of the illness. This corroborates earlier conclusions that especially in young children influenza virus infections are clinically indistinguishable from other respiratory viral infections, and they cannot be reliably identified without the use of specific diagnostic tests.

The duration of symptoms before the initial visit to the study clinic was shorter in children with influenza A than in those with influenza B. It is therefore possible that the early symptoms of influenza A infection are more prominent in infants than symptoms caused by influenza B viruses. Although this finding suggests a need for further studies, it is also possible that the observed difference was due to chance only, because ample recent data indicate that there are no differences in the clinical presentation of influenza A and B virus infections in children. Furthermore, no other differences between influenza A and B were observed in this study.

Although the point estimate of the effectiveness of influenza vaccination of infants in our study was 48%, it was not statistically significant. This is in line with the nationwide analysis conducted by the Finnish Institute for Health and Welfare, concluding that no effectiveness could be shown for the trivalent inactivated influenza vaccine used during the season of our study. Because vaccine effectiveness was low not only in children but also in adults, it could well explain why vaccination of all other family members in our study did not reduce the incidence of influenza in the infants. In the absence of an influenza vaccine that could be administered to infants under 6 months of age, many health authorities emphasize the importance of vaccinating all household members and other close contacts to protect infants from influenza. It is important to notice that our results do not demonstrate that such a “cocooning” strategy would not work in principle. It is just an inconvenient fact that during seasons when there is a substantial mismatch between the vaccine and circulating strains of influenza, no major benefit, either direct or indirect, can be expected from vaccination against influenza.

The strengths of our study include close follow-up of a large cohort of infants who were enrolled without any exclusion criteria, easy and free access to the study clinic that was open every day during the 10-month study period, careful clinical examination and routine re-examinations during each illness, collection of nasopharyngeal swabs during each illness irrespective of the severity of symptoms, and daily recording of the infants’ symptoms in the diaries by the parents. The main limitation of our study is that it covered only a single influenza season; conducting studies with similar setup during several consecutive seasons would increase the accuracy of the estimates. Furthermore, the final numbers of children with influenza were relatively small, which resulted in reduced power to show statistically significant differences especially between influenza A and B viruses.

In conclusion, our study provides new and detailed information about influenza in young infants during their first influenza season. Besides the relatively high rates of influenza-associated hospitalization among the youngest infants, the burden of illness is heavy also in the outpatient setting where most infants with influenza are managed. Because influenza vaccines are licensed only for children older than 6 months and the duration of protection afforded by maternal antibodies is limited, effective strategies for the prevention of influenza particularly in infants under 6 months of age are needed to diminish the burden of disease in this age group.

**ACKNOWLEDGEMENTS**

This study was supported by a research grant from Janssen Pharmaceutica NV Belgium to Turku University Hospital, Finland. ArcDia International Ltd, Turku, Finland, provided the rapid antigen detection tests for the study. J-MM has received personal grants from the Finnish Cultural Foundation, the Tuberculosis Foundation of Tampere, University of Turku, the Foundation of Väinö and Laina Kivi, and the Duodecim Society of Turunmaa.
CONFLICTS OF INTEREST
TH has received consulting fees from AstraZeneca, Sanofi Pasteur, and Seqirus. The other authors have no conflicts to report.

AUTHOR CONTRIBUTION
Janna-Majja Mattila: Conceptualization (supporting); Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal); Writing-original draft (lead); Writing-review & editing (supporting). Emilia Thomas: Investigation (equal); Writing-review & editing (supporting). Pasi Lehtinen: Investigation (equal); Writing-review & editing (supporting). Tytti Vuorinen: Methodology (equal); Writing-review & editing (supporting). Matti Waris: Methodology (equal); Writing-review & editing (supporting). Terho Heikkinen: Conceptualization (lead); Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal); Project administration (lead); Supervision (lead); Writing-review & editing (lead).

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Terho Heikkinen https://orcid.org/0000-0001-6504-0116

REFERENCES
1. Wang X, Li Y, O’Brien KL, et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob Health. 2020;8(4):e497-e510.
2. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342:225-231.
3. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232-239.
4. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355:31-40.
5. Silvennoinen H, Peltola V, Vainionpää R, Ruuskanen O, Heikkinen T. Incidence of influenza-related hospitalizations in different age groups of children in Finland: a 16-year study. Pediatr Infect Dis J. 2011;30:e24-e28.
6. Heikkinen T, Tsoila M, Finn A. Vaccination of healthy children against seasonal influenza: a European perspective. Pediatr Infect Dis J. 2013;32:881-888.
7. Silvennoinen H, Peltola V, Vainionpää R, Ruuskanen O, Heikkinen T. Admission diagnoses of children 0–16 years of age hospitalized with influenza. Eur J Clin Microbiol Infect Dis. 2012;31:225-231.
8. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med. 2005;353:2559-2567.
9. Shang M, Blanton L, Brummer L, Olsen SJ, Fry AM. Influenza-associated pediatric deaths in the United States, 2010–2016. Pediatrics. 2018;141:e20172918.
10. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L. Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001;344:889-896.
11. Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010;303:943-950.
12. Walter EB, Rajagopai S, Zhu Y, Neuzil KM, Fairchok MP, Englund JA. Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine. 2010;28:4376-4383.
13. Jarvis JR, Dorey RB, Warricker FDM, Alwan NA, Jones CE. The effectiveness of influenza vaccination in pregnancy in relation to child health outcomes: systematic review and meta-analysis. Vaccine. 2020;38:1601-1613.
14. Nunes MC, Cutland CL, Jones S, et al. Duration of infant protection against influenza illness conferred by maternal immunization: secondary analysis of a randomized controlled trial. JAMA Pediatr. 2016;170:840-847.
15. Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Bernier D. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season. MMWR Recomm Rep. 2019;68(No. RR-3):1-21.
16. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-133.
17. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. Clin Infect Dis. 2010;51:887-894.
18. Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and safety of oseltamivir in children: Systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis. 2018;66:1492-1500.
19. Fell DB, Johnson J, Mor Z, et al. Incidence of laboratory-confirmed influenza disease among infants under 6 months of age: a systematic review. BMJ Open. 2017;7:e016526.
20. Teros-Jaakkola T, Toivonen L, Schuez-Havupalo L, et al. Influenza virus infections from 0 to 2 years of age: A birth cohort study. J Microbiol Immunol Infect. 2019;52:526-533.
21. Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. J Infect Dis. 2004;190:1369-1373.
22. Somes MP, Turner RM, Dwyer LJ, Newall AT. Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: a systematic review and meta-analysis. Vaccine. 2018;36:3199-3207.
23. Heikkinen T, Thint M, Chomnaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med. 1999;340:260-264.
24. Chomnaitree T, Revai K, Grady JJ, et al. Viral upper respiratory tract infection and otitis media complication in young children. N Engl J Med. 2008;361:815-823.
25. Heikkinen T, Ruuskanen O. Temporal development of acute otitis media during upper respiratory tract infection. Pediatr Infect Dis J. 1994;13:659-661.
26. Koivunen P, Kontio K, Niemelä M, et al. Time to development of acute otitis media during upper respiratory tract infection in children. Pediatr Infect Dis J. 1999;18:303-305.
27. Silvennoinen H, Peltola V, Lehtinen P, Vainionpää R, Heikkinen T. Clinical presentation of influenza in unselected children treated as outpatients. Pediatr Infect Dis J. 2009;28:372-375.
28. Heinonen S, Peltola V, Silvennoinen H, Vahberg T, Heikkinen T. Signs and symptoms predicting influenza in children: a matched case-control analysis of prospectively collected clinical data. Eur J Clin Microbiol Infect Dis. 2012;31:1569-1574.
29. Danier J, Rivera L, Claey S, et al. Clinical presentation of influenza in children 6 to 35 months of age: findings from a randomized clinical trial of inactivated quadrivalent influenza vaccine. Pediatr Infect Dis J. 2019;38:866-872.
30. Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. *Lancet*. 2001;358:1410–1416.

31. Peltola V, Reunanen T, Ziegler T, Silvennoinen H, Heikkinen T. Accuracy of clinical diagnosis of influenza in outpatient children. *Clin Infect Dis*. 2005;41:1198–1200.

32. Silvennoinen H, Huusko T, Vuorinen T, Heikkinen T. Comparative burden of influenza A/H1N1, A/H3N2 and B infections in children treated as outpatients. *Pediatr Infect Dis J*. 2015;34:1081–1085.

33. Tran D, Vaudry W, Moore D, et al. Hospitalization for influenza A versus B. *Pediatrics*. 2016;138:e20154643.

34. Streng A, Priifert C, Weissbrich B, Sauerbrei A, Schmidt-Ott R, Liese JG. Subtype-specific clinical presentation, medical treatment and family impact of influenza in children 1–5 years of age treated in outpatient practices in Germany during three postpandemic years, 2013–2015. *Pediatr Infect Dis J*. 2018;37:861–867.

35. Mattila JM, Vuorinen T, Heikkinen T. Comparative severity of influenza A and B infections in hospitalized children. *Pediatr Infect Dis J*. 2020;39:489–493.

36. Baum U, Kulathinal S, Auranen K, Nohynek H. Effectiveness of two influenza vaccines in nationwide cohorts of Finnish two-year-old children in the seasons 2015/16–2017/18. *Clin Infect Dis*. 2020. https://doi.org/10.1093/cid/ciaa050

37. Ikonen N, Murtopuro S, Haveri A, et al. Influenssakausi Suomessa, viikot 40/2017-20/2018: Seurantaraportti. Finland: National Institute for Health and Welfare; 2018. http://urn.fi/URN:ISBN:978-952-343-159-1. Accessed September 18, 2020.

How to cite this article: Mattila J-M, Thomas E, Lehtinen P, Vuorinen T, Waris M, Heikkinen T. Burden of influenza during the first year of life. *Influenza Other Respi Viruses*. 2021;15:506–512. https://doi.org/10.1111/irv.12820